Trial Profile
A Single-Dose, Open-Label, Randomized, Food Effect Study in Healthy Volunteers With PT2977 Tablets
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Belzutifan (Primary)
- Indications Iron overload; Pulmonary arterial hypertension; Solid tumours
- Focus Pharmacokinetics
- Sponsors Peloton Therapeutics
- 13 Nov 2018 Status changed from not yet recruiting to completed.
- 28 Feb 2018 New trial record